Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 6, 2012, Pages 934-942

  Vlassara, Helen ^a   Uribarri, Jaime ^a   Cai, Weijing ^a   Goodman, Susan ^a   Pyzik, Renata ^a   Post, James ^a,b   Grosjean, Fabrizio ^a,c   Woodward, Mark ^d   Striker, Gary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Division of Nephrology   (Italy)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; 8 ISOPROSTANE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BICARBONATE; CALCIUM CARBONATE; CHLORIDE; CYSTATIN C; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLGLYOXAL; PHOSPHATE; POTASSIUM; SEVELAMER CARBONATE; SIRTUIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PH; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOLOGICAL MARKERS; CALCIUM; CALCIUM CARBONATE; CHELATING AGENTS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DINOPROST; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY; LEUKOCYTES; LIPIDS; MALE; MIDDLE AGED; NEW YORK CITY; OXIDATIVE STRESS; PHOSPHORUS; POLYAMINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862223183     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12891211     Document Type: Article

References (48)

1. Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS: Risk for ESRD in type 1 diabetes remains high despite renoprotection. J AmSoc Nephrol 22: 545-553, 2011
2. Burrows NR, Li Y, Geiss LS: Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 33: 73-77, 2010
3. Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB: Oral diabetes medications for adults with type 2 diabetes: An update. In: Comparative Effectiveness Review, No. 27, Rockville, MD, Agency for Healthcare Research and Quality, 2011
4. Vlassara H, Striker GE: AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol 7: 526-539, 2011
5. Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A: Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 89: 27-71, 2009
6. Chao PC, Huang CN, Hsu CC, Yin MC, Guo YR: Association of dietaryAGEswith circulatingAGEs, glycated LDL, IL-1a andMCP-1 levels in type 2 diabetic patients. Eur J Nutr 49: 429-434, 2010
7. Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, Strauch CM, Monnier VM, Doria A, Aiello LP, King GL: Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: The Joslin 50-year medalist study. Diabetes Care 34: 968-974, 2011
8. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27: 605-614, 2007
9. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; Collaborative Study Group: Pyridorin in type 2 diabetic nephropathy. J AmSoc Nephrol 23: 131-136, 2012
10. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 34: 1610-1616, 2011
11. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, Vlassara H: Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 173: 327-336, 2008
12. Leslie RD, Beyan H, Sawtell P, Boehm BO, Spector TD, Snieder H: Level of an advanced glycated end product is genetically determined: A study of normal twins. Diabetes 52: 2441-2444, 2003
13. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T; Chronic Kidney Disease Prognosis Consortium: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 79: 1341-1352, 2011
14. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149: 820-825, 2005
15. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A: Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57: 422-431, 2011
16. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA: Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3: 1125-1130, 2008
17. Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, Moysés RM: FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 6: 241-247, 2011
18. Shantouf R, Budoff MJ, Ahmadi N, Tiano J, Flores F, Kalantar-Zadeh K: Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 28: 275-279, 2008
19. Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM: Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 5[Suppl 1]: S31-S40, 2010
20. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
21. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72: 1255-1261, 2007
22. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
23. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J AmDiet Assoc 104: 1287-1291, 2004
24. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94: 6474-6479, 1997
25. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H: Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62: 427-433, 2007
26. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE, Uribarri J: Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94: 4483-4491, 2009
27. Cai W, He JC, Zhu L, Lu C, Vlassara H: Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 103: 13801-13806, 2006
28. Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H: AGEreceptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 294: C145-C152, 2008
29. Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E: Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 29: 195-201, 2002
30. Mitsuhashi T, Li YM, Fishbane S, Vlassara H: Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 100: 847-854, 1997
31. Woodward M: Epidemiology: Study Design and Data Analysis, Boca Raton, FL, CRC Press, 2005
32. Urribarri JCC, Ramdas M, Goodman S, Pyzik R, Chen L, Zu L, Striker GE, Vlassara H: Improved innate defenses after restricting AGE intake reduces insulin resistance in type 2 diabetes: Role of AGER1 and SIRT1. Diabetes Care 34: 1610-1616, 2011
33. He C, Sabol J, Mitsuhashi T, Vlassara H: Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48: 1308-1315, 1999
34. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A Correlation of glucose regulation and hemoglobin A1C. J Biochem 252: 2992-2997, 1977
35. Paynter NP, Mazer NA, Pradhan AD, Gaziano JM, Ridker PM, Cook NR: Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. Arch Intern Med 171: 1712-1718, 2011
36. Bays HE, Goldberg RB, Truitt KE, Jones MR: Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch Intern Med 168: 1975-1983, 2008
37. Vega GL, Dunn FL, Grundy SM: Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol 108: 1129-1135, 2011
38. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
39. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov IG, Vanholder R, Lacour B, Drüeke TB, Massy ZA: Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112: 2875-2882, 2005
40. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653-1661, 2003
41. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD: Metabolic syndrome and kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 6: 2364-2373, 2011
42. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J AmSoc Nephrol 14: 728-731, 2003
43. Mirza MA, AlsiöJ, Hammarstedt A, Erben RG, Michaëlsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellström D, Lind L, Ohlsson C, Larsson TE: Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31: 219-227, 2011
44. Bili A, Sartorius JA, Kirchner HL, Morris SJ, Ledwich LJ, Antohe JL, Dancea S, Newman ED, Wasko MC: Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 17: 115-120, 2011
45. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R:Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111: 1448-1454, 2005
46. Agrawal V, Marinescu V, Agarwal M, McCullough PA: Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat Rev Cardiol 6: 301-311, 2009
47. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389, 2000
48. Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L: Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 26: 379-385, 2011